| | | | |

Protein May Help Predict Complications After Peritoneal Mesothelioma Surgery

ByAlex Strauss

Researchers at MD Anderson Cancer Center say they may have found a way to help predict which peritoneal mesothelioma patients are most likely to develop complications after cytoreductive surgery and intraperitoneal chemotherapy.

Cytoreductive surgery to remove as much of a mesothelioma tumor as possible, followed by a rinse of heated chemotherapy drugs in the abdomen is known as CRS + HIPEC. It has become a standard treatment for people with the abdominal form of the asbestos cancer known as malignant peritoneal mesothelioma.

In a new study, researchers analyzed cases of all patients who underwent CRS + HIPEC at MD Anderson between June of 2014 and February of 2016 to find commonalities among those who did not do well. Their findings may help improve outcomes for some mesothelioma patients.

CRS + HIPEC for Peritoneal Mesothelioma Treatment

CRS + HIPEC is used to treat several different types of cancer that occur in the abdomen. Peritoneal mesothelioma tumors grow on the peritoneal membrane which lines the abdomen and holds the fluid that allows organs to move freely and without friction inside the abdomen. It is an extremely rare cancer affecting only about 500 people in the US each year.

Of the 129 patients identified for the new study, 16 had a diagnosis of peritoneal mesothelioma.

According to the new report, 12 percent of the CRS + HIPEC patients studied developed major complications, 13 percent experienced cardiopulmonary complications (related to the heart and lungs,) and 18 percent developed both.

Protein May Be Biomarker for Mesothelioma Treatment Complications

Researchers did find a commonality among patients who struggled following their CRS + HIPEC treatment. Those with major/cardiopulmonary complications were more likely to have an elevated level of B-type natriuretic peptide (BNP), a protein produced by the heart during heart failure.

Elevated BNP is also associated with adverse cardiac outcomes after other types of surgeries.

Disturbingly, this association was most pronounced in the CRS + HIPEC patients who were also being treated with cisplatin, one of the two primary drugs used in the treatment of mesothelioma.

For every 100 unit increase in the BNP on the first day after a patient’s CRS + HIPEC procedure, the risk of major/cardiopulmonary complications was 7.4 versus 1.2 for the remaining patients.

“Multivariate analysis identified increased EBL (blood loss) and a trend toward increased BNP on postoperative day 1 as risk factors for major/CP complications,” writes MD Anderson surgical oncologist Sarah B. Fisher, MD, in a summary of the study in the Journal of Surgical Oncology.

The researchers conclude that measuring the postoperative BNP level of malignant mesothelioma patients and others who have undergone CRS + HIPEC may help to identify patients at risk for major and/or cardiopulmonary complications.

If such complications can be predicted ahead of time, clinicians are more likely to be able to intervene in ways that may maximize mesothelioma survival.

Source:

Fisher, SB, et al, “Elevated brain natriuretic peptide (BNP) is an early marker for patients at risk for complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC)”, November 28, 2017, Journal of Surgical Oncology, Epub ahead of print, http://onlinelibrary.wiley.com/doi/10.1002/jso.24904/full

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…